BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: NHL: Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight

May 06, 2021

Cutaneous T-cell lymphomas (CTCLs) are comprised of a heterogeneous group of rare non-Hodgkin’s lymphomas which primarily affect the skin, but may also affect the bone marrow, lymph nodes, blood, and viscera. Symptoms of CTCL may include a red rash, enlarged lymph nodes, dry skin, and severe itching.

The exact mechanism of disease initiation and its progression is unknown. Abnormalities in some genes and signaling pathways have been reported, but their exact role in the disease pathogenesis has not been elucidated. Older individuals are generally more prone to CTCLs, and compared to women, men are more likely to develop the disease. Additionally, people with a suppressed immune system and those with human T-cell lymphotropic virus type 1 (HTLV-1) infection are at a higher risk of developing the disease.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Cutaneous T-Cell Lymphoma (CTCL) - NHL
Back to the top Back to the top